Literature DB >> 30250928

CDC25 as a common therapeutic target for triple-negative breast cancer - the challenges ahead.

Eldad Zacksenhaus1,2,3, Jeff C Liu1, Letizia Granieri1,4, Ioulia Vorobieva1,2, Dong-Yu Wang1, Ronak Ghanbari-Azarnier1,2, Huiqin Li1, Amjad Ali1, Philip E D Chung1,2, YoungJun Ju1, Zhe Jiang1, Mariusz Shrestha1,2.   

Abstract

The dual phosphatase CDC25 has recently been identified as a target for diverse triple-negative breast cancers including RB1/PTEN/P53-deficient tumors. Moreover, CDC25 inhibitors effectively synergize with PI3K inhibitors to suppress tumor growth. We discuss these findings and the challenges that lie ahead in bringing CDC25 inhibitors to the clinic.

Entities:  

Keywords:  CDC25 inhibitors; PTEN; RB1; Triple negative breast cancer; p53; therapy

Year:  2018        PMID： 30250928      PMCID： PMC6149702          DOI： 10.1080/23723556.2018.1481814

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Discovery of new inhibitors of Cdc25B dual specificity phosphatases by structure-based virtual screening.

Authors:  Antonio Lavecchia; Carmen Di Giovanni; Ada Pesapane; Nunzia Montuori; Pia Ragno; Nicola Massimiliano Martucci; Mariorosario Masullo; Emmanuele De Vendittis; Ettore Novellino
Journal:  J Med Chem       Date:  2012-05-01       Impact factor: 7.446

Review 2.  Mitochondrial OXPHOS Induced by RB1 Deficiency in Breast Cancer: Implications for Anabolic Metabolism, Stemness, and Metastasis.

Authors:  Eldad Zacksenhaus; Mariusz Shrestha; Jeff C Liu; Ioulia Vorobieva; Philip E D Chung; YoungJun Ju; Uri Nir; Zhe Jiang
Journal:  Trends Cancer       Date:  2017-10-17

3.  The RB-IL-6 axis controls self-renewal and endocrine therapy resistance by fine-tuning mitochondrial activity.

Authors:  S Kitajima; A Yoshida; S Kohno; F Li; S Suzuki; N Nagatani; Y Nishimoto; N Sasaki; H Muranaka; Y Wan; T C Thai; N Okahashi; F Matsuda; H Shimizu; T Nishiuchi; Y Suzuki; K Tominaga; N Gotoh; M Suzuki; M E Ewen; D A Barbie; O Hirose; T Tanaka; C Takahashi
Journal:  Oncogene       Date:  2017-05-08       Impact factor: 9.867

4.  Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.

Authors:  R Condorelli; L Spring; J O'Shaughnessy; L Lacroix; C Bailleux; V Scott; J Dubois; R J Nagy; R B Lanman; A J Iafrate; F Andre; A Bardia
Journal:  Ann Oncol       Date:  2018-03-01       Impact factor: 32.976

Review 5.  RB1 and p53 at the crossroad of EMT and triple-negative breast cancer.

Authors:  Zhe Jiang; Robert Jones; Jeff C Liu; Tao Deng; Tyler Robinson; Philip E D Chung; Sharon Wang; Jason I Herschkowitz; Sean E Egan; Charles M Perou; Eldad Zacksenhaus
Journal:  Cell Cycle       Date:  2011-05-15       Impact factor: 4.534

6.  RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.

Authors:  Robert A Jones; Tyler J Robinson; Jeff C Liu; Mariusz Shrestha; Veronique Voisin; YoungJun Ju; Philip E D Chung; Giovanna Pellecchia; Victoria L Fell; SooIn Bae; Lakshmi Muthuswamy; Alessandro Datti; Sean E Egan; Zhe Jiang; Gustavo Leone; Gary D Bader; Aaron Schimmer; Eldad Zacksenhaus
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

Review 7.  CDC25 phosphatases in cancer cells: key players? Good targets?

Authors:  Rose Boutros; Valérie Lobjois; Bernard Ducommun
Journal:  Nat Rev Cancer       Date:  2007-07       Impact factor: 60.716

8.  Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer.

Authors:  Agnieszka K Witkiewicz; Sejin Chung; Rachel Brough; Paris Vail; Jorge Franco; Christopher J Lord; Erik S Knudsen
Journal:  Cell Rep       Date:  2018-01-30       Impact factor: 9.423

9.  High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factors.

Authors:  Tyler J W Robinson; Melody Pai; Jeff C Liu; Frederick Vizeacoumar; Thomas Sun; Sean E Egan; Alessandro Datti; Jing Huang; Eldad Zacksenhaus
Journal:  Cell Cycle       Date:  2013-08-12       Impact factor: 4.534

10.  Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer.

Authors:  Jeff C Liu; Letizia Granieri; Mariusz Shrestha; Dong-Yu Wang; Ioulia Vorobieva; Elizabeth A Rubie; Rob Jones; YoungJun Ju; Giovanna Pellecchia; Zhe Jiang; Carlo A Palmerini; Yaacov Ben-David; Sean E Egan; James R Woodgett; Gary D Bader; Alessandro Datti; Eldad Zacksenhaus
Journal:  Cell Rep       Date:  2018-04-03       Impact factor: 9.995
  10 in total
  3 in total

1.  A Potential Anticancer Mechanism of Finger Root (Boesenbergia rotunda) Extracts against a Breast Cancer Cell Line.

Authors:  Muhammad Hermawan Widyananda; Septian Tri Wicaksono; Kurnia Rahmawati; Sapti Puspitarini; Siti Mariyah Ulfa; Yoga Dwi Jatmiko; Masruri Masruri; Nashi Widodo
Journal:  Scientifica (Cairo)       Date:  2022-09-05

2.  Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion.

Authors:  Susumu Kohno; Paing Linn; Naoko Nagatani; Yoshihiro Watanabe; Sharad Kumar; Tomoyoshi Soga; Chiaki Takahashi
Journal:  Oncogene       Date:  2020-07-21       Impact factor: 9.867

3.  Inhibition mechanism of naphthylphenylamine derivatives acting on the CDC25B dual phosphatase and analysis of the molecular processes involved in the high cytotoxicity exerted by one selected derivative in melanoma cells.

Authors:  Federica Aliotta; Rosarita Nasso; Rosario Rullo; Alessandro Arcucci; Angelica Avagliano; Martina Simonetti; Gennaro Sanità; Mariorosario Masullo; Antonio Lavecchia; Maria Rosaria Ruocco; Emmanuele De Vendittis
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.